[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial - Hofman, MS; Emmett, L; Sandhu, S (The Lancet, 2021)
et al.